The cervix center at Hopkins coordinates all aspects of HPV disease. Our emphasis is on patient care, education and outreach. Because of exciting discoveries from our research, we are also in a position to offer the opportunity to participate in clinical trials. These trials will offer new vaccine therapies.
Cervical cancer is a sexually transmitted disease.
Over 90 strains of HPV have been identified. The most common cause of LSIL, HSIL and cancer is HPV16. The vaccine trials are targeted at HPV16. The first study will determine the normal immune response to HSIL caused by HPV16. All participants will be screened for HPV type.